MAP2K3 and diabetes mellitus: We also demonstrated that mutation of ctRAGE is sufficient to interrupt both RAGE binding to MKK3 and RAGE activation of the p38MAPK/NF‐κB signaling pathway, as well as to diminish diabetes‐induced neural damage and behavioral impairments.